Skip to content
HomeLatest newsWorking together to tackle vaccine-preventable disease in children
GAVI

Working together to tackle vaccine-preventable disease in children

Share Article
share to

This week in Berlin, Gavi, The Vaccine Alliance, an organization which improves access to new and underused vaccines for children, brought together world leaders and stakeholders to welcome new commitments towards its mission to immunize children in developing countries. I am proud to say that Janssen, the pharmaceutical companies of Johnson & Johnson, were a part of this group which pledged a total of US$7.5 billion, which will enable countries to immunize an additional 300 million children.

I would personally like to congratulate the world community and Gavi on this renewed commitment and pledge which is expected to help save an estimated five to six million lives by 2020. In the 15 years since the international organization Gavi was founded, half a billion children have already received lifesaving vaccines through their work.

As a parent myself, I believe the dramatic decline in preventable child deaths during the past 25 years is one of humankind’s greatest achievements. Deadly and debilitating diseases are entirely preventable through immunization and by investing in vaccines, we can do far more than protect health; we can also protect people’s incomes and savings, and promote economic growth.

Despite this accomplishment, we must remain committed to reducing child mortality. Johnson & Johnson has a deep commitment and long heritage in supporting children’s health so while attending the Gavi meeting we also pledged to make the vaccine QUINVAXEM® available at Gavi prices tograduating countries (who have passed the eligibility threshold). In order to protect as many children as possible, we believe it is our duty to ensure this vaccine remains as affordable as possible. This combination “five-in-one” vaccine is key to protecting children from diphtheria, pertussis (whooping cough), tetanus, hepatitis B and Haemophilus influenzae type b (Hib) which causes pneumonia and meningitis.

By working with Gavi and our other partners to improve global health, we are doing our best to ensure that every child, around the world, receives the vaccines they need to grow up and develop to their full potential.

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.